Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
David Lang
Observed names:
D Lang,
D. Lang,
Lang, David
Institutions:
Johannes Kepler University of Linz,
Kepler Universitätsklinikum
Observed institutions:
Johannes Kepler University of Linz,
Innsbruck Medical University,
Universität Innsbruck,
Kepler Universitätsklinikum
ORCID:
0000-0002-3098-1554
Observed ORCID:
0000-0002-3098-1554
OpenAlex ID:
A5090637958
IgG4-related disease: current challenges and future prospects
2016
·
David Lang
, Jochen Zwerina
, et al.
·
Therapeutics and Clinical Risk Management
·
109
PDF
Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade
2019
·
Florian Huemer
, David Lang
, et al.
·
Journal of Clinical Medicine
·
72
PDF
Impact of PET/CT for Assessing Response to Immunotherapy—A Clinical Perspective
2020
·
David Lang
, Gerald Wahl
, et al.
·
Journal of Clinical Medicine
·
62
PDF
Complications of CT-guided transthoracic lung biopsy: A short report on current literature and a case of systemic air embolism
2018
·
David Lang
, Viktoria Reinelt
, et al.
·
Wiener klinische Wochenschrift
·
58
PDF
Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: the EMPIRE registry study
2022
·
Dragana M. Jovanovic
, Martina Šterclová
, et al.
·
Respiratory Research
·
56
PDF
Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC—A retrospective cohort study
2019
·
David Lang
, Andreas Horner
, et al.
·
Lung Cancer
·
48
Association between antibiotics use and outcome in patients with NSCLC treated with immunotherapeutics
2019
·
F. Huemer
, G. Rinnerthaler
, et al.
·
Annals of Oncology
·
25
Screening for rheumatoid arthritis-associated interstitial lung disease—a Delphi-based consensus statement
2024
·
Klaus Hackner
, Lisa Hütter
, et al.
·
Zeitschrift für Rheumatologie
·
24
PDF
Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study
2019
·
David Lang
, Florian Huemer
, et al.
·
Targeted Oncology
·
24
PDF
Serum tumor markers for response prediction and monitoring of advanced lung cancer: A review focusing on immunotherapy and targeted therapies
2023
·
Michel van den Heuvel
, Stefan Holdenrieder
, et al.
·
Tumor Biology
·
22
PDF
First-Line Pembrolizumab Mono- or Combination Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict Outcomes
2021
·
David Lang
, Linda Ritzberger
, et al.
·
Cancers
·
21
PDF
Clinical, imaging, and blood biomarkers to assess 1-year progression risk in fibrotic interstitial lung diseases—Development and validation of the honeycombing, traction bronchiectasis, and monocyte (HTM)-score
2022
·
Guangyu Shao
, Patricia Hawle
, et al.
·
Frontiers in Medicine
·
15
Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy—A Retrospective Bi-Centric Cohort Study
2021
·
David Lang
, Anna Brauner
, et al.
·
Cancers
·
15
PDF
Anti‐Inflammatory Effects and Prediction of Blood Pressure Response by Baseline Inflammatory State in Catheter‐Based Renal Denervation
2016
·
David Lang
, Alexander Nahler
, et al.
·
Journal of Clinical Hypertension
·
15
Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study
2020
·
David Lang
, Wolfgang Haslinger
, et al.
·
Lung Cancer Targets and Therapy
·
11
PDF
Computed Tomography Findings as Determinants of Local and Systemic Inflammation Biomarkers in Interstitial Lung Diseases: A Retrospective Registry-Based Descriptive Study
2021
·
David Lang
, Kaveh Akbari
, et al.
·
Lung
·
10
PDF
SUV as a Possible Predictor of Disease Extent and Therapy Duration in Complex Tuberculosis
2017
·
David Lang
, Helmut Huber
, et al.
·
Clinical Nuclear Medicine
·
10
Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort
2026
·
Oliver Illini
, Anna-Carina Hund
, et al.
·
Journal of Thoracic Oncology
·
9
PDF
Computed tomography findings as determinants of pulmonary function tests in fibrotic interstitial lung diseases—Network-analyses and multivariate models
2020
·
David Lang
, Kaveh Akbari
, et al.
·
Chronic Respiratory Disease
·
8
PDF
Prognostic Implications of Volume-based Quantitative 18F-FDG PET/CT Biomarkers in Pulmonary Sarcoidosis
2025
·
Guangyu Shao
, Bernhard Kaiser
, et al.
·
Clinical Nuclear Medicine
·
5
Transmission electron microscopy of transbronchial lung cryobiopsy samples in a cohort of fibrotic interstitial lung disease patients – feasibility and implications of endothelial alterations
2024
·
David Lang
, Walter Stoiber
, et al.
·
Respiratory Research
·
5
PDF
Antibody–drug conjugates (ADCs) in lung cancer treatment
2024
·
Romana E. Wass
, David Lang
, et al.
·
memo - Magazine of European Medical Oncology
·
5
PDF
Functional Improvement at One Year in Fibrotic Interstitial Lung Diseases—Prognostic Value of Baseline Biomarkers and Anti-Inflammatory Therapies
2024
·
Guangyu Shao
, Paul Thöne
, et al.
·
Diagnostics
·
4
Checkpoint inhibitor pneumonitis: Short review of literature and case report
2021
·
Romana Elisabeth Wass
, David Lang
, et al.
·
memo - Magazine of European Medical Oncology
·
4
PDF
Positionspapier der ÖGR und ÖGP zur Diagnose und Therapie der Sarkoidose 2024
2024
·
Georg Sterniste
, Klaus Hackner
, et al.
·
Wiener klinische Wochenschrift
·
3
PDF
Show more works
View as search
Works count:
64
Citation count:
661
H-index:
14
I10-index:
17
Year
Topic
Type